Floatz logo

Cediranib

Estrogen Receptor Negative

National Cancer Institute (NCI)Small moleculePhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Estrogen Receptor Negative cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Epirubicin
Massachusetts General Hospital
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Washington
Phase 3BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →